Pionyr Immunotherapeutics

United States
South San Francisco, California, United States, 94080

Company profile

Pionyr Immunotherapeutics company profile

Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company’s approach, Myeloid Tuning™, is designed to enhance the immune system’s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.

Business identity

Contact email
[email protected]
Phone number
(415)226-7503
Operating status
Closed
Company type
For Profit
Employee range
51-100 employees
Revenue range
$0-$1M
Founded
2015-01-01, Year

Headquarters

Postal code
94080
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
4
Total equity funding
$352M
Last funding
Corporate Round / $275M / 2020-06-23
Last equity funding
Corporate Round / $275M
Investors
13
Lead investors
6
Founders
2
Articles
18
Exited on
2023-08-07

Founders and investors

Founders

Max KrummelSachdev Sidhu

Lead investors

Gilead SciencesNew Enterprise AssociatesOrbiMedSofinnova InvestmentsSV Health InvestorsVida Ventures

Investors

Mission BioCapitalNew Enterprise AssociatesOrbiMedOUP (Osage University Partners)SV Health Investors